<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02264899</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2012/32</org_study_id>
    <nct_id>NCT02264899</nct_id>
  </id_info>
  <brief_title>MEMENTO-VAScular COmponents of Dementia</brief_title>
  <acronym>VASCOD</acronym>
  <official_title>MEMENTO-VAScular COmponents of Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry for Health and Solidarity, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter national longitudinal cohort study including at least 800 individuals recruited
      from French Research Memory Centers and followed up over 36 months and included in Memento.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease (AD) is a neurodegenerative disorder thought to be caused by the
      accumulation of the peptide amyloid beta and the hyperphosphorylated tau protein in the
      brain. There are increasing arguments in favor of an important role of vascular damages in
      the development and progression of AD.

      The time course of these vascular alterations and how they relate to dementia and AD
      pathology remain unclear, as no protocol that allows the development of the diverse vascular
      pathology to be scored, and hence to be tracked with ageing, has so far been developed and
      widely validated. The aims of this project are to investigate, in a large clinical sample of
      patients presenting either isolated cognitive complaints or light to mild cognitive deficits,
      how vascular risk factors and vascular alterations (assessed at macro and micro levels)
      relate to cerebrovascular disease and cognitive decline.

      The primary objective of this ancillary study is to investigate the prospective association
      between vascular risk factors, inflammation markers and vascular damages on cognitive decline
      and neurodegeneration progression over up to 4 years of follow-up in a sample of individuals
      presenting with a spectrum of cognitive profiles ranging from isolated cognitive complaints
      to cognitive deficits without dementia.

      The secondary objectives are the following

        -  To investigate the role of vascular risk factors (diabetes, hypertension,
           hypercholesterolemia) and vascular damages on progression to clinical dementia over up
           to 4-year follow-up.

        -  To study whether the interaction between changes in markers of macrovascular and
           microvascular structures on cognitive deficits progression.

        -  To study the association between in BP, hypertension, antihypertensive treatments and
           vascular damages, progression of cerebrovascular disease seen at MRI and cognitive
           decline and dementia risk

        -  To assess the temporality of vascular damages burden on neurodegeneration

        -  To assess the association between retinal vasculature defect and brain neurovascular
           damages

        -  To study the link between vascular damages and AD pathology (Cerebro-Spinal Fluid (CSF)
           and Positron emission tomography (TEP) amyloid imaging) biomarkers in the subsample of
           participants having all measures available

        -  To investigate how inflammatory markers mediate the association between vascular damages
           and neurodegeneration

        -  To assess whether vascular factors and neurodegenerative factors act independently or
           synergistically on the course of cognitive decline

        -  To assess simultaneously the impact of vascular damages on end organs (brain, eye, and
           kidney)

        -  To study the correlation between cerebral blood flow, measured by Arterial spin-Labeled
           (ASL) MRI and cognitive decline

        -  To study whether genetic polymorphisms revealed from genome-wide association studies
           (GWAS) of AD of vascular factors could modulate the association between vascular damages
           and cognitive decline
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognitive performances over</measure>
    <time_frame>36 months from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression to clinical dementia of Alzheimer's type according to standardized criteria</measure>
    <time_frame>36 months from baseline</time_frame>
    <description>standardized criteria : Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and National Institute of Neurological and Communicative Disorders and Stroke Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) classifications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF and blood amyloid biomarkers of AD</measure>
    <time_frame>24 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in brain atrophy and hippocampal volumes</measure>
    <time_frame>24 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of small vessels disease markers (white matter lesions, lacunar infarcts, microbleeds)</measure>
    <time_frame>24 months from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Alzheimer's Disease (AD)</condition>
  <condition>Alzheimer's Disease (AD) Related Disorders</condition>
  <arm_group>
    <arm_group_label>Alzheimer's disease and related disorders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>in Memento-VASCOD</intervention_name>
    <description>Pulse wave velocity assessment
Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences
Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement
Neuropsychological testing and behaviorial and mood scales
Urinary albumin excretion measurement</description>
    <arm_group_label>Alzheimer's disease and related disorders</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants to MEMENTO-Vascod should be included in MEMENTO.

          -  To have signed a specific MEMENTO-Vascod informed consent form, prior to any Vascod
             ancillary study related procedures

          -  To be aged 50 years old and above

          -  To have a Clinical Dementia Rating scale &lt;0.5 and to be not demented;

        Exclusion Criteria:

          -  Are under guardianship

          -  Live in skilled nursing facility

          -  Are Pregnant or breast feeding women

          -  Meet brain MRI exclusion criteria (Same criteria as in Memento main protocol)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Genevieve CHENE, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC-EC1401 - ISPED - CHU de Bodeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geneviève CHENE, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>CIC-EC1401 - ISPED - CHU de Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carole DUFOUIL, Director</last_name>
    <role>Study Director</role>
    <affiliation>CIC-EC1401 - ISPED - CHU de Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geneviève CHENE, Prof.</last_name>
    <phone>(0)5 57 57 13 92</phone>
    <phone_ext>+33</phone_ext>
    <email>genevieve.chene@isped.u-bordeaux2.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carole DUFOUIL, Director</last_name>
    <phone>(0)5 57 57 14 23</phone>
    <phone_ext>+33</phone_ext>
    <email>carole.dufouil@isped.u-bordeaux2.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier GODEFROY, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Olivier GODEFROY, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François DARTIGUES, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Jean-François DARTIGUES, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier ROUAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier ROUAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence PASQUIER, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Florence PASQUIER, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre KROLAK-SALMON, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Pierre KROLAK-SALMON, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu CECCALDI, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Mathieu CECCALDI, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey GABELLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Audrey GABELLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital BROCA</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier HANON, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Olivier HANON, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital LARIBOISIERE</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques HUGON, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Jacques HUGON, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric BLANC, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric BLANC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

